The mechanism of action and main indications of ensifentrine-Ohtuvayre

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is a new drug that treats chronic obstructive pulmonary disease (COPD) by inhibiting the action mechanism of PDE3 and PDE4 enzymes. Inhibition of these two enzymes, PDE3 and PDE4, can increase the levels of intracellular cAMP (cyclic adenosine monophosphate) and/or cGMP (cyclic guanosine monophosphate), thereby triggering a series of physiological reactions, ultimately achieving the effects of relieving COPD symptoms, reducing airway inflammation, and dilating the bronchi.

COPD is a common chronic respiratory disease, which mainly manifests symptoms such as long-term shortness of breath, chronic cough, and excessive phlegm, which brings great trouble to patients' quality of life. Traditional treatments for COPD include bronchodilators and anti-inflammatory drugs, but many patients do not respond well to existing treatments or only experience partial relief of symptoms. The emergence of exefantine provides a new treatment option for this type of patients. By enhancing the dilation effect of the bronchi and reducing inflammation, it can significantly improve the patient's respiratory function and relieve symptoms caused by airway stenosis and inflammation.

The main indication of ensefentin is for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. In patients with COPD, the drug works through a dual mechanism of action. It is not only effective in relieving acute symptoms, but can also significantly improve the patient's quality of life in long-term maintenance treatment. It can relieve symptoms such as coughing, shortness of breath, and shortness of breath, and can help reduce the frequency of exacerbations. For patients with COPD, treatment with exefantine can stabilize the patient's condition in the long term, thereby reducing the need for hospitalization due to worsening of the condition. Its efficacy also makes it an alternative option for some patients who do not respond well to existing treatment options.

Keyword tags: Ensifentrine, Ensifentrine, Ohtuvayre, drug mechanism, chronic obstructive pulmonary disease, COPD, bronchiectasis, drug indications, PDE3 inhibitors, PDE4 inhibitors

Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6433c98-41a0-4f99-8f7f-d0e9db6e3f40